Cooley LLP announced today that it advised Revance Therapeutics, Inc. on its $110 million IPO. Revance is a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications. It now trades on the NASDAQ Global Stock Market under the symbol “RVNC.”
The Cooley corporate and securities team advising Revance included partners Mark Weeks, chair of Cooley’s medical device practice, and Gordon Ho, as well as special counsel Marina Remennik, and associates Rose Standifer, Patty Cheng, Josh Seidenfeld and Sale Kwon. Critical support for the offering was provided by partners Natasha Leskovsek (regulatory), Mark Windfeld-Hansen (tax) and Renee Deming (compensation and benefits).
This offering follows Cooley’s record year for capital markets work in 2013 in which the firm advised on 60 public offerings, including 23 IPOs, raising more than $8.4 billion. Year-to-date, Cooley has advised on 20 public offerings, including 10 IPOs.
